[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ascites-hepatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ascites-hepatic":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,73,98,125,155,182,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100495097","qol-and-sarcopenia-in-patients-with-ascites-100495097",false,"NCT05726747","QOL and Sarcopenia in Patients With Ascites","Health-related Quality of Life Outcomes and Changes in Sarcopenia in Patients With Refractory Ascites","Inclusion Criteria:\n\n1. Age \\>\u002F=18\n2. Eastern Cooperative Oncology Group (ECOG) performance score \\\u003C 3\n3. Refractory ascites due to cirrhosis or malignancy, requiring more than 1 therapeutic paracentesis in a 6 week period within 3 months of enrollment.\n4. Capable of giving informed consent\n\nExclusion Criteria:\n\n1. Life expectancy less than 3 months\n2. Unable to participate in neuropsychological tests\u002Fquestionnaires\n3. Pregnant or nursing women. .","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","OBSERVATIONAL","Clinical data regarding quality of life in patients with refractory ascites is limited and preceded the development of newer questionnaires that may be more robust. One primary objective of this study is to study changes in quality in life in a prospective fashion using newer general and ascites-specific quality of life survey instruments specific to benign and malignant etiologies.\n\nSarcopenia is a condition that is prevalent in cancer and cirrhosis. Current data is retrospective and associative, evaluating heterogeneous patient populations at different stages within the timeline of refractory ascites. The other primary objective of this study is to study sarcopenia in a prospective fashion and to understand its kinetics once a patient develops refractory ascites.\n\nProspectively-obtained measures of deterioration in patient-reported outcomes and in muscle mass will form the basis for the next stage of investigation of interventions to mitigate these declines.",[24,25],"Ascites Hepatic","Ascites, Malignant",[27,28],"ascites","sarcopenia","RECRUITING","2026-06-12",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":35,"type":33},"2023-05-23",{"date":37,"type":20},"2027-10",{"name":39,"class":40},"Abramson Cancer Center at Penn Medicine","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100560422","early-tips-in-patients-with-liver-cirrhosis-and-ascites-100560422","NCT06576934","Early TIPS in Patients With Liver Cirrhosis and Ascites","Early Implantation of a Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Patients With Liver Cirrhosis and Ascites: a Multicentre, Randomised Controlled Trial","eTIPS","Inclusion Criteria:\n\nPatients eligible for inclusion in this trial must meet all of the following criteria:\n\n1. Patients ≥ 18 years and \\\u003C 80 years\n2. Liver cirrhosis as documented by previous liver biopsy or by a combination of typical clinical, biochemical and sonographic features\n3. Ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites\n4. INR ≤ 1.5\n5. Ability to understand the nature of the trial and the trial related procedures and to comply with them\n\nExclusion Criteria:\n\nPatients eligible for this trial must not meet any of the following criteria:\n\n1. Treatment refractory or recurrent ascites at the time of study inclusion\n2. Patients with concomitant variceal bleeding fulfilling the criteria for pre-emptive TIPS implantation (Child-Pugh class C \\\u003C 14 points or Child-Pugh class B \\>7 with active bleeding at initial endoscopy or hepatic venous pressure gradient \\[HVPG\\] \\> 20 mmHg at the time of bleeding)\n3. Budd-Chiari syndrome\n4. Portal vein thrombosis (PVT)\n5. Spontaneous bacterial peritonitis (SBP)\n6. Uncontrolled systemic infection (defined as an increase of \\> 20% if inflammatory parameters \\[C-reactive protein, procalcitonin, leukocytes\\] and\u002For sepsis as a reason for development of ascites\n7. Cardiac cirrhosis (defined as the development of liver cirrhosis in a patient with cardiac heart failure due to primary cardiac disease)\n8. Clinical significant cardiac disease (NYHA ≥II)\n9. Untreated valvular heart disease: middle to high-grade valve stenosis or insufficiency (applies to mitral, tricuspid, aortic and pulmonary valves)\n10. Diastolic dysfunction grade III, stated by transthoracic echocardiogram (TTE)\n11. Reduced left ventricular ejection fraction ≤50%\n12. Pulmonary hypertension (mean pulmonary arterial pressure \\> 45 mmHg)\n13. Bilirubin \\> 3 mg\u002Fdl\n14. Obstructive cholestasis\n15. Hepatorenal syndrome type AKI (HRS-AKI)\n16. Acute on chronic liver failure\n17. Benign liver tumor within the potential puncture tract\n18. Patient after liver transplantation\n19. Prior TIPS implantation\n20. Ongoing and\u002For recurrent hepatic encephalopathy (grade \\>II)\n21. Active tumor disease including hepatocellular carcinoma defined as need for chemotherapy, radiation therapy, interventional or surgical treatment\n22. New onset of antiviral treatment for chronic hepatitis B virus (HBV) infection within the last 3 months\n23. Untreated chronic hepatitis C virus (HCV) infection\n24. Life expectancy \\\u003C1 year\n25. Pregnant or breastfeeding women\n26. Patients without the legal capacity who are unable to understand the nature, significance and consequences of the study\n27. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed\n28. Person who is in a relationship of dependence\u002Femployment with the sponsor or the investigator","80 Years",{"count":52,"type":20},134,"INTERVENTIONAL",[55],"NA","The aim of this clinical trial is to compare the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) implantation with standard treatment (diuretic medications, and if necessary, paracenteses) in patients with liver cirrhosis and development of ascites as the first decompensating event.\n\nBy creating a shunt between the liver vein and the portal vein, blood is diverted from the portal vein directly into the hepatic vein, which results in a reduction of pressure in the portal vein so that development of ascites is reduced.",[58,24,59],"Liver Cirrhosis","Portal Hypertension",[61,62,27,63],"liver cirrhosis","Transjugular intrahepatic portosystemic shunt","MELD","2026-04-27",{"date":66,"type":33},"2026-05-01",{"date":68,"type":33},"2025-04-01",{"date":70,"type":20},"2029-02-15",{"name":72,"class":40},"University Hospital Freiburg",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":53,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100619825","underdilated-stent-technique-improves-post-tips-encephalopathy-100619825","NCT07349654","Underdilated-stent Technique Improves Post-TIPS Encephalopathy","Underdilated-stent Technique Improves Post-transjugular Intrahepatic Portosystemic Shunt Encephalopathy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Liver cirrhosis, defined by clinical manifestations, biochemical indicators, imaging examinations, or liver biopsy;\n* History of esophagogastric variceal bleeding, or refractory\u002Frecurrent ascites;\n* Intended to undergo TIPS treatment.\n\nExclusion Criteria:\n\n* Non-cirrhotic portal hypertension;\n* Previous treatments that may affect portal pressure, such as TIPS or surgical procedures;\n* History of overt hepatic encephalopathy (West-Haven classification ≥2);\n* Malignant tumors in advanced stages;\n* Concomitant irreversible heart, liver, kidney, or respiratory failure;\n* Unable or unwilling to sign the informed consent form.","75 Years",{"count":82,"type":20},72,[55],"Transjugular intrahepatic portosystemic shunt (TIPS) is a critical therapeutic approach for managing esophagogastric variceal bleeding and refractory ascites in decompensated cirrhosis patients. To date, hepatic encephalopathy (HE) remains one of the most common complications following TIPS procedures, and prediction and prevention of post-TIPS HE have always been a hotspot in the field of hepatology. However, no reliable clinical studies have confirmed that any drug or intervention can effectively prevent the occurrence of HE episodes following TIPS, including lactulose and rifaximin.\n\nUnderdilated strategy (UDS) was reported as an development technique proposed in recent years for TIPS procedures, which involves using a small-diameter balloon to dilate the puncture tract and subsequently implanted standard-diameter covered stent (e.g., 8 mm). This allows the stent to maintain a smaller diameter shortly after release, thereby reducing the incidence of hepatic encephalopathy during the postoperative period. Over time, the stent gradually dilates to its normal diameter within months. This period coincides with the higher incidence risk of post-TIPS HE, most commonly occurring within 6 months, especially within the first 3 months after TIPS. Therefore, theoretically, UDS can reduce the occurrence of post-TIPS HE. In terms of clinical research, however, there were still no high quality studies reported the advantages of this technique. Current reported clinical studies were all non-randomized controlled trials or retrospective studies, with low-quality evidence and sometimes contradictory findings.\n\nThe aim of this prospective randomized controlled clinical study is to evaluate whether administration of underdilated technology during TIPS can improve postoperative hepatic encephalopathy, without compromising the therapeutic efficacy of portal hypertension complications.",[58,86,24,87],"Variceal Bleeding, Cirrhosis","Hepatic Encephalopathy (HE)","2026-01-09",{"date":90,"type":33},"2026-01-20",{"date":92,"type":33},"2024-11-19",{"date":94,"type":20},"2027-12-31",{"name":96,"class":40},"The Second Affiliated Hospital of Chongqing Medical University",2,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":105,"targetDuration":4,"studyType":53,"phases":107,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":41},"100567562","effectiveness-and-safety-of-tips-stent-graft-in-the-treatment-of-cirrhosis-and-complications-of-portal-hypertension-100567562","NCT06669806","Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension","A Prospective, Multi-Center, Single-Arm Clinical Study to Evaluate the Effectiveness and Safety of LIVERTYTM TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension","Inclusion Criteria:\n\n1. The subject who is 18 years old or above but 75 years old or below;\n2. The subject who is diagnosed with portal hypertension caused by liver cirrhosis with the history of gastrointestinal variceal bleeding or bleeding, hepatic hydrothorax, and refractory or recurrent ascites;\n3. The subject must have adequate functional hepatic reserve with a Model for End-Stage Liver Disease (MELD) Score of ≤13 or Child-Pugh Score of ≤18;\n4. The subject with platelet count≥ 20×10\\^9 \u002FL;\n5. Subjects or their guardians who can understand the content of the clinical trial, voluntarily participate in the clinical trial and sign the ICF and can complete the follow-up period according to the requirements of the clinical trial.\n\nExclusion Criteria:\n\n1. The subject who is pregnant or lactating or plan to get pregnant during the clinical trial;\n2. According to the judgment of investigator, the subject with main portal vein thrombosis which thrombus occupying \\>50% of the portal vein lumen and affecting postoperative hemodynamics;\n3. The subject who has received surgical or interventional treatment (such as TIPS, surgical shunt and retrograde transvenous obliteration (-RTO) for treatment of complications from portal hypertension. Note: The subject who have received -RTO for variceal bleeding at least 8 weeks before signing the informed consent form can be included in the clinical trial;\n4. The subject who needs to receive or have received splenectomy;\n5. The subject who has received or plan to receive liver transplantation;\n6. The subject who cannot have a shunt channel established in the liver parenchyma between the hepatic vein and the portal vein as determined by the investigators;\n7. The subject with extrahepatic or hepatic malignancies;\n8. The subject with Budd-Chiari syndrome and hepatic sinusoidal obstruction syndrome;\n9. The subject with congenital cystic dilatation of bile duct (Caroli disease) and obstructive dilation of biliary tract;\n10. The subject with polycystic liver disease;\n11. The subject with cavernous transformation of the portal vein;\n12. The subject with severe or refractory hepatic encephalopathy (Grade 2 or above according to the West Haven Criteria);\n13. The subject with a TBIL level higher than 51.3 μmol\u002FL (excluding the Patients with cholestatic cirrhosis);\n14. The subject with coagulation disorders (INR: \\>2.5);\n15. The subject with a systolic pressure lower than 80 mmHg;\n16. The subject with severe tricuspid regurgitation or congestive heart failure;\n17. The subject with myocardial infarction within the past 3 months;\n18. The subject with moderate to severe pulmonary arterial hypertension, or severe hepatopulmonary syndrome;\n19. The subject with uncontrolled systemic infection or inflammation;\n20. The subject with severe renal insufficiency (Scr level:\\>199.5 μmol\u002FL) or needing to receive dialysis;\n21. The subject known to be allergic to the contrast media or to the constituent materials of the TIPS covered segment;\n22. The subject with the history of epilepsy or mental illness or with cognitive impairment;\n23. The subject with the expected survival time of less than 1 year;\n24. The subject who is otherwise determined as ineligible for participation in this Study by investigators;\n25. The subject who is participating in any other unfinished drug or medical device clinical trials.",{"count":106,"type":20},166,[55],"This Study is a prospective, multi-center, single-arm objective perform an criteria (OPC) study. A 12 months follow-up study on the patients who intend to receive the treatment of cirrhosis and complications of portal hypertension with the TIPS Stent Graft will be conducted. The primary evaluation endpoint of this Study is the stent patency at 6 months after treatment completion .",[110,24,111],"Portal Hypertension Related to Cirrhosis","Variceal Bleeding",[62,113,114],"TIPS stent","patency","2025-12-18",{"date":117,"type":33},"2025-12-19",{"date":119,"type":33},"2024-11-21",{"date":121,"type":20},"2027-01-01",{"name":123,"class":124},"C. R. Bard","INDUSTRY",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":132,"targetDuration":4,"studyType":53,"phases":134,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100476971","phase-1-single-and-multiple-dose-escalation-of-phin-214-in-child-pugh-a-and-b-liver-cirrhotics-100476971","NCT05490888","Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics","A Phase 1 Open Label Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults With Child Pugh A and B Cirrhosis","Key Inclusion Criteria:\n\n1. History of cirrhosis based on histology or a combination of clinical, radiological, or biochemical assessment and classified as Child-Pugh A or B\n2. Participants may be male or female aged 18 to 75 years.\n3. Body mass index (BMI) within the range 18 to 40 kg\u002Fm2 (inclusive) at screening.\n4. Female participants must be non-pregnant, non-lactating, or of non-childbearing potential or using highly efficient contraception for the full duration of the study\n\nKey Exclusion Criteria:\n\n1. Significant abnormalities in medical history or on physical examination, including: respiratory disease requiring therapy or history of respiratory failure, cardiovascular disease or hypertension, electrocardiogram abnormalities or history of significant EKG abnormalities.\n2. History of diabetes insipidus, syndrome of inappropriate antidiuretic hormone secretion, or any other disorder associated with fluid or sodium imbalance.\n3. Significant kidney disease\n4. Hepatic encephalopathy (HE) or altered mental status requiring hospitalization; variceal bleeding or upper gastrointestinal bleeding; or type 1 hepatorenal syndrome with acute kidney injury (HRS-AKI) during the previous 3 months prior to Screening.\n5. Acute-on-chronic liver failure.\n6. Recipient of a patent transjugular intrahepatic portosystemic shunt (TIPS).\n7. Known positive HIV serology confirmed by HIV viral load.\n8. Subjects with acute infections, including acute viral hepatitis (subjects with chronic hepatitis B are eligible if treatment regimen is stable ≥ 3 months prior to study inclusion).",{"count":133,"type":20},74,[135],"PHASE1","This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.",[138,139,24],"Cirrhosis, Liver","Liver Fibrosis",[141,142,143,144],"Terlipressin","Cirrhosis","Vasoconstrictor","Refractory Ascites","2025-09-03",{"date":147,"type":33},"2025-09-05",{"date":149,"type":33},"2022-01-03",{"date":151,"type":20},"2026-06-30",{"name":153,"class":124},"PharmaIN",9,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":53,"phases":164,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":41},"100578522","phase-2-albumin-assisted-diuresis-in-patients-with-cirrhosis-and-ascites-100578522","NCT06812390","Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites","Albumin Assisted Diuresis in Patients with Cirrhosis Decompensated by Ascites and Peripheral Edema, a Proof-of-concept Double Blind Randomized Trial","Inclusion Criteria:\n\n* Outpatient patients with decompensated cirrhosis with past or current ascites and persistent lower extremity edema despite oral diuretic titration\n* Serum albumin of \\\u003C 3.5 g\u002FdL\n* Age \\>=18 years old\n\nExclusion Criteria:\n\n* Patients with GFR \\\u003C 30mL\u002Fmin\u002F1.73 m2\n* Changes in oral diuretic regimen in the past 7 days (\\*\\*patients can enter the study after 7 days of the change)\n* Large Volume paracentesis (LVP) in the past 7 days (\\*\\*patients can enter the study after 7 days)\n* Albumin infusion within the previous 14 days (\\*\\* patients can enter the study after 14 days)\n* Spontaneous Bacterial Peritonitis in the past month\n* Active variceal bleeding\n* Current Hepatic encephalopathy (\\>= Grade 2 based on West Haven criteria)\n* Co-administration of other diuretics such as Hydrochlorothiazide (amiloride or eplerenone in place of spironolactone, and Bumex\u002FTorsemide in place of furosemide are acceptable)\n* Hypotension (Mean Arterial Pressure \\\u003C65 mmHg, Systolic Blood pressure \\\u003C90 mmHg)\n* Severe hyponatremia (Sodium \\\u003C125 mEq\u002FL)\n* previous diagnosis of overt heart failure (systolic EF \\\u003C 50%)\n* Baseline oxygen requirement\n* Hypersensitivity to albumin preparations",{"count":163,"type":20},20,[165],"PHASE2","A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.",[142,24],[169,170,27,171],"albumin","cirrhosis","diuresis","2025-03-10",{"date":174,"type":33},"2025-03-11",{"date":176,"type":33},"2025-02-28",{"date":178,"type":20},"2027-03",{"name":180,"class":181},"Anahita Rabiee MD MHS","FED",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":190,"targetDuration":4,"studyType":53,"phases":192,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":210},"100465874","hrs-aki-treatment-with-tips-in-patients-with-cirrhosis-100465874","NCT05346393","HRS-AKI Treatment With TIPS in Patients With Cirrhosis","Hepatorenal Syndrome-acute Kidney Injury (HRS-AKI) Treatment With Transjugular Intrahepatic Portosystemic Shunt in Patients With Cirrhosis. A Randomized Controlled Trial","Liver-HERO","Inclusion Criteria:\n\n1. Patients with cirrhosis confirmed by histology or liver stiffness or with unequivocal signs in ultrasound, endoscopy and\u002For blood tests\n2. Clinically evident ascites due to portal hypertension\n3. HRS-AKI\n4. Age: ≥ 18 to ≤ 80 years old at the time of consent\n5. ECOG \\\u003C 4 prior to hospital admission\n6. Subject has been informed of the nature of the study, is willing to comply with all required follow-up evaluations within the defined follow-up visit windows and has signed an Ethics Committee (EC) approved consent form.\n7. Female subjects of childbearing potential have a negative pregnancy test ≤ 7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation. Female subjects will be exempted from this requirement in case they are sterile, infertile, or have been post-menopausal for at least 12 months (no menses). A contraceptive method with a pearl index below 1% is assumed to be effective.\n\nExclusion Criteria:\n\n1. Recent or current use of nephrotoxic drugs (NSAIDS, Aminoglycosides or high-dosed iodinated contrast medium) in the previous 72 hours before AKI diagnosis\n2. Improvement of renal function after 1 day of diuretic removal and plasma volume expansion with albumin 1-1.5 gr\u002Fkg\n3. Uncontrolled shock within the last 48 hours prior to randomization\n4. Patients with uncontrolled infection (defined by a 20 % increase in inflam-matory parameters (CRP, leucocytes or insufficient decrease of PMN in ascitic fluid \\\u003C 25 % from baseline in the case of a SBP) despite 48 hours of antibiotic treatment.\n5. Patients with cardiac cirrhosis as defined by the development of cirrhosis in a patient with chronic heart failure due to a primary cardiac disease (is-chemic cardiomyopathy, hypertensive cardiomyopathy, etc.)\n6. Patients with contraindications to TIPS placement (e.g. Bilirubin \\> 85.5 µmol\u002FL (≙ 5 mg\u002FdL), recurrent hepatic encephalopathy, clinically relevant pulmonary hypertension, aortic stenosis)\n7. Patients with cavernous portal vein thrombosis, splenic vein thrombosis or mesenteric vein thrombosis\n8. Patients with clinically significant cardiac disease (NYHA ≥ II)\n9. Patients with diastolic dysfunction grade 3.\n10. Patients with a reduced systolic function with an ejection fraction ≤ 50 %\n11. Patients with ACLF grade 3\n12. Patients with creatinine value \\> 442 µmol\u002FL (≙ 5 mg\u002FdL)\n13. Patients with an acute variceal bleeding at the time of screening who have indication for pre-emptive TIPS and\u002For terlipressin.\n14. Patients with refractory ascites as defined by the International Ascites Club (\\\u003C 800 gr weight loss over 4 days in patients on low salt diet and high dose diuretics (spironolactone 400 mg \u002Fday and furosemide \\* 160 mg \u002Fday), or lower dose of diuretics with complications secondary to the use of diuretics such as hyponatremia, renal failure, hepatic encephalopathy. \\*equivalent dose of torasemide 40 mg\u002Fday\n15. Patients with hepatocellular carcinoma outside of the Milan criteria\n16. Patients with hepatocellular carcinoma within the Milan criteria in whom the tumor is located in the puncture tract.\n17. Patients with benign liver tumors (except regenerative nodules) which are located in the puncture tract.\n18. Patients who already have a TIPS placed\n19. Patients who already had a liver transplantation\n20. Patients with other comorbidities that lead to an estimated life expectancy under 1 year.\n21. Patients with respiratory insufficiency which requires mechanical ventila-tion\n22. Patients with circulatory failure which requires administration of other vas-opressors (catecholamines)\n23. Patients receiving renal replacement therapy\n24. The subject is currently enrolled in another investigational device or drug trial.\n25. Patients with pregnancy or lactation\n26. Patients which are suspected to be incompliant for study participation.",{"count":191,"type":20},124,[55],"The study compares the effectiveness and safety of TIPS implantation in patients with HRS-AKI (stage1, 2 and 3) and liver cirrhosis with standard therapy (drug therapy with terlipressin + albumin).",[138,195,196,24],"Hepatorenal Syndrome","Acute Kidney Injury",[198,196,142,195,199,200,141],"Ascites","TIPS","transjugular intrahepatic portosystemic shunt","2024-11-14",{"date":203,"type":33},"2024-11-18",{"date":205,"type":33},"2022-11-29",{"date":207,"type":20},"2026-06",{"name":209,"class":40},"Jena University Hospital",14,{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":41},"100533300","predictive-values-of-presepsin-levels-in-ascites-in-patients-with-chronic-liver-failure-100533300","NCT06224023","Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure","PASS","Inclusion Criteria:\n\n* patient with ascites and chronic liver failure\n* no contraindications and technical possibility to perform diagnostic paracentesis\n* age above 18 years old\n* informed consent\n\nExclusion Criteria:\n\n* contraindications to paracentesis or technical impossibility to perform paracentesis\n* absence of informed consent",{"count":219,"type":20},30,"The investigators aim to study the predictive value of presepsin in ascites in newly admitted patients with chronic liver failure.",[24,222,138],"Liver Failure","2024-08-20",{"date":225,"type":33},"2024-08-21",{"date":227,"type":33},"2024-08-01",{"date":229,"type":20},"2024-12-31",{"name":231,"class":40},"Carol Davila University of Medicine and Pharmacy"]